Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration

Insilico agreed to apply its Pharma.AI platform, which addresses target validation, generative chemistry, and molecule optimization, along with its preclinical drug discovery expertise to discover, design, and optimize candidates for neuroimmune indications against targets that will originate with SK. SK will contribute its development and clinical capabilities in neuroimmune disorders, steering the late-stage development and commercialization of all resulting programs.

The post Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News.